Johnson & Johnson (NYSE:JNJ) Citi's 2018 Global Healthcare Conference December 5, 2018 10:15 AM ET
Executives
Matt Stuckley - IR
Joe Wolk - EVP and CFO
Analysts
Amit Hazan - Citi
Andrew Baum - Citi
Amit Hazan
For those of you that don't know me, this is the J&J Presentation. I've got all the way to the far left of me, Andrew Baum, who's the Pharma Analyst who co-covers J&J with me. We got Joe Wolk, the newly minted CFO here to have a discussion.
Before we do that, we're going to have a Safe Harbor statement to be read by Matt Stuckley from IR. Go ahead.
Matt Stuckley
Thanks Amit. Good morning everyone. Please be aware that some statements made today may be considered forward-looking or utilize non-GAAP measures. Please refer to our SEC filings, in particular, our 10-K, which discuss the risk and uncertainties around forward-looking statements as well as our website at investor.jnj.com for reconciliations to comparable GAAP measures. Finally, any performance measures made today represent results through and including the third quarter of 2018. Thank you. Amit?
Question-and-Answer Session
Q - Amit Hazan
Great. So, Joe, I think this is -- if I'm not mistaken, this is your first fireside chat as a CFO. You've probably done one or two of these in your prior role. Joe, you took over about five months ago. And so I thought, obviously, the first question should be how everything's been these first five months. Every CFO has got their own fingerprint and you're going to have yours. We're sure about that. So, what's the experience been like for the first five months? And what is that fingerprint for you? What are you seeing and changing at J&J?
